| Literature DB >> 28293974 |
Martin Lagging1, Rune Wejstål1,2, Gunnar Norkrans1, Olle Karlström3, Soo Aleman4, Ola Weiland4, Maria Castedal5, Johan Westin1.
Abstract
In a recent expert meeting, Swedish recommendations for the treatment of hepatitis C virus (HCV) infection were updated. An interferon-free combination of direct-acting antiviral agents is considered and indicated for all patients with chronic HCV infection, but the ability to treat all is limited primarily by high cost of medication. The group of patients prioritized for therapeutic intervention has been extended to also include fertile women desiring to become pregnant. A more thorough discussion of treatment for people who inject drugs (PWIDs) in order to diminish transmission is included, and the clinical significance of baseline NS5A resistance associated variants (RAVs), also known as resistance associated substitutions (RASs), for the treatment of HCV genotype 1a or 3 infection is discussed.Entities:
Keywords: Children; Chronic kidney disease; Direct-acting antiviral agents; Genotype; Guidelines; HIV co-infection; Hepatitis C virus; People who inject drugs; Resistance associated substitutions; Resistance associated variants
Mesh:
Substances:
Year: 2017 PMID: 28293974 DOI: 10.1080/23744235.2017.1300682
Source DB: PubMed Journal: Infect Dis (Lond) ISSN: 2374-4243